{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:22:11Z","timestamp":1790400131211,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.leukres.2016.08.006","type":"journal-article","created":{"date-parts":[[2016,8,13]],"date-time":"2016-08-13T03:20:48Z","timestamp":1471058448000},"page":"108-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1 35INS"],"prefix":"10.1016","volume":"49","author":[{"given":"Ellin","family":"Berman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Jhanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Hedvat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Arcila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Abdel-","family":"Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Maloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Albitar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2016.08.006_bib0005","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.leukres.2016.08.006_bib0010","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2016.08.006_bib0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0092-8674(84)90438-0","article-title":"An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity","volume":"37","author":"Konopka","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2016.08.006_bib0020","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/315758a0","article-title":"Structural organization of the bcr gene and its role in the Ph\u2019 translocation","volume":"315","author":"Heisterkamp","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2016.08.006_bib0025","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2016.08.006_bib0030","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five year follow up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.08.006_bib0035","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six year follow up of patients receiving imatinib for first line treatment of chronic myelogenous leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2016.08.006_bib0040","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.leukres.2016.08.006_bib0045","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1073\/pnas.0409770102","article-title":"Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation \u2212specific binding in resistance","volume":"102","author":"Burgess","year":"2005","journal-title":"PNAS"},{"key":"10.1016\/j.leukres.2016.08.006_bib0050","first-page":"355","article-title":"Dasatinib in chronic myelogenous leukemia","volume":"1062","author":"Chu","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.08.006_bib0055","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1158\/1535-7163.MCT-08-0482","article-title":"BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence for molecular dynamic simulations","volume":"7","author":"Lee","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2016.08.006_bib0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2353\/jmoldx.2008.070128","article-title":"press RD. An intron-derived insertion\/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy","volume":"10","author":"Laudadio","year":"2008","journal-title":"J. Mol. Diagn."},{"issue":"8","key":"10.1016\/j.leukres.2016.08.006_bib0065","article-title":"The BCR-ABL35INS insertion\/truncation mutant is kinase-inactive and does not contribute to resistance in chronic myeloid leukemia","volume":"10","author":"O\u2019Hare","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.006_bib0070","first-page":"342","article-title":"on behalf of the European LeukemiaNet","volume":"370","author":"Hehlman","year":"2007","journal-title":"Chronic myeloid leukemia. The Lancet"},{"key":"10.1016\/j.leukres.2016.08.006_bib0075","unstructured":"http:\/\/www.nccn.org\/professionals\/physician gls\/pdf\/chronic myelogenous leukemia."},{"key":"10.1016\/j.leukres.2016.08.006_bib0080","series-title":"National Institute of Health","author":"Common terminology criteria of adverse events (CTCAE) v3.0","year":"2010"},{"key":"10.1016\/j.leukres.2016.08.006_bib0085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.tig.2003.12.004","article-title":"How prevalent is functional alternative splicing in the human genome","volume":"20","author":"Sorek","year":"2004","journal-title":"Trends Genet."},{"key":"10.1016\/j.leukres.2016.08.006_bib0090","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1021\/pr034064v","article-title":"Assessing the impact of alternative splicing on domain interactions in the human proteome","volume":"3","author":"Resch","year":"2004","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.leukres.2016.08.006_bib0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev.biochem.76.050106.093909","article-title":"The nonsense-mediated decay RNA surveillance pathway","volume":"76","author":"Chang","year":"2007","journal-title":"Ann. Rev. Biochem."},{"key":"10.1016\/j.leukres.2016.08.006_bib0100","first-page":"15","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"355","author":"Papaemmanuil","year":"2011","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.08.006_bib0105","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nature10496","article-title":"Frequent pathway mutations of splicing machinery in myelodysplasia","volume":"478","author":"Yoshida","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2016.08.006_bib0110","first-page":"422","article-title":"The spliceosomes as an indicted conspirator in myeloid malignancies","author":"Abdel- Wahab","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2016.08.006_bib0115","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Wang","year":"2011","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.08.006_bib0120","unstructured":"http:\/\/www.cancernetwork.com\/cancer-management\/CML."},{"key":"10.1016\/j.leukres.2016.08.006_bib0125","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/leu.2015.168","article-title":"Bradley- Garelnik MS, Ukropec J, Hcohhaus A. BCR-ABL1 mutation development during firwt line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase","volume":"29","author":"Hughes","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2016.08.006_bib0130","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1073\/pnas.84.14.4890","article-title":"Effect of premature termination of translation on mRNA stability depends on the site of ribosome release","volume":"84","author":"Nilsson","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.leukres.2016.08.006_bib0135","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1101\/gad.17268411","article-title":"Ending the message: poly(A) signals then and now","volume":"25","author":"Proudfoot","year":"2011","journal-title":"Genes Dev."},{"key":"10.1016\/j.leukres.2016.08.006_bib0140","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood-2014-06-581926","article-title":"MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.006_bib0145","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High sensitivity detection of BCR\u2013ABL kinase domain mutations in imatinib na\u00efve patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.006_bib0150","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib and newly diagnosed chronic phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.08.006_bib0155","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2016","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.08.006_bib0160","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nature10662","article-title":"RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)","volume":"480","author":"Poulikakos","year":"2011","journal-title":"Nature"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616301709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616301709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T02:57:33Z","timestamp":1536461853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616301709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":32,"alternative-id":["S0145212616301709"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.08.006","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL135INS","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}